Banhiran Wish, Assanasen Paraya, Nopmaneejumrudlers Cherdchai, Nujchanart Nongyoaw, Srechareon Wimontip, Chongkolwatana Cheerasook, Metheetrairut Choakchai
Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Siriraj Sleep Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Laryngoscope. 2018 Feb;128(2):516-522. doi: 10.1002/lary.26753. Epub 2017 Jul 17.
OBJECTIVES/HYPOTHESIS: To compare outcomes of continuous positive airway pressure (CPAP) and the adjustable thermoplastic mandibular advancement splint (AT-MAS) for obstructive sleep apnea treatment.
Randomized crossover, noninferiority, tertiary center setting.
Fifty patients with a mean age of 49.5 ± 10.6 years were enrolled. Inclusion criteria were age ≥18 years, apnea-hypopnea index (AHI) ≥5 events/hour, and oxygen saturation ≥70%. Exclusion criteria were temporomandibular joint disorders, severe periodontitis, inadequate teeth, and unstable medical diseases. Treatment intolerance was considered a failure. Two-week periods without treatment were followed by questionnaires and randomization into two groups: CPAP/AT-MAS (25) and AT-MAS/CPAP (25). After 6 weeks of intervention, questionnaires and home WatchPAT monitoring were performed. Following each 2-week washout period, patients crossed over to the other treatment followed by similar procedures. Primary outcomes involved the scores from the Functional Outcomes of Sleep Questionnaire (FOSQ). Secondary outcomes were AHI, side effects, and treatment adherence.
Seven patients withdrew from this study: five (AT-MAS intolerance) and two (lost follow-up). There was no significant difference among FOSQ scores, particularly on global scores, between both treatments (0.57, 95% confidential interval of difference: -0.15 to 1.29). Mean AHI decreased from pretreatment 39.2 ± 2.53 to 2.56 ± 0.49 and 12.92 ± 2.05 events/hour while using CPAP and the AT-MAS, respectively (P < .05). Most common side effects of CPAP were dry throat and inconvenience to carry, whereas those of the AT-MAS were jaw pain and excessive salivation.
Both devices improved short-term quality of life similarly; however, the AT-MAS was not as efficacious as CPAP on resolving sleep-test parameters. The AT-MAS might be considered only a temporary treatment alternative.
1b. Laryngoscope, 128:516-522, 2018.
目的/假设:比较持续气道正压通气(CPAP)和可调节热塑性下颌前移矫治器(AT-MAS)治疗阻塞性睡眠呼吸暂停的效果。
随机交叉、非劣效性、三级中心研究。
纳入50例平均年龄为49.5±10.6岁的患者。纳入标准为年龄≥18岁、呼吸暂停低通气指数(AHI)≥5次/小时、血氧饱和度≥70%。排除标准为颞下颌关节紊乱、重度牙周炎、牙齿缺失和不稳定的内科疾病。治疗不耐受被视为治疗失败。在两周未治疗期后进行问卷调查,并随机分为两组:CPAP/AT-MAS组(25例)和AT-MAS/CPAP组(25例)。干预6周后,进行问卷调查和家庭WatchPAT监测。在每2周的洗脱期后,患者交叉接受另一种治疗,随后进行类似的程序。主要结局包括睡眠功能结局问卷(FOSQ)的评分。次要结局为AHI、副作用和治疗依从性。
7例患者退出本研究:5例(AT-MAS不耐受)和2例(失访)。两种治疗方法的FOSQ评分,尤其是总体评分,差异无统计学意义(0.57,差异的95%置信区间:-0.15至1.29)。使用CPAP和AT-MAS时,平均AHI分别从治疗前的39.2±2.53降至2.56±0.49和12.92±2.05次/小时(P<.05)。CPAP最常见的副作用是咽干和携带不便,而AT-MAS的副作用是颌部疼痛和唾液过多。
两种装置对改善短期生活质量的效果相似;然而,AT-MAS在改善睡眠测试参数方面不如CPAP有效。AT-MAS可能仅被视为一种临时的治疗选择。
1b。《喉镜》,2018年,第128卷,第516 - 522页